292 related articles for article (PubMed ID: 30232558)
21. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.
Bokemeyer C; Beyer J; Metzner B; Ruther U; Harstrick A; Weissbach L; Kohrmann U; Verbeek W; Schmoll HJ
Ann Oncol; 1996 Jan; 7(1):31-4. PubMed ID: 9081388
[TBL] [Abstract][Full Text] [Related]
22. Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial.
Necchi A; Lo Vullo S; Giannatempo P; Raggi D; Calareso G; Togliardi E; Crippa F; Pennati M; Zaffaroni N; Perrone F; Busico A; Colecchia M; Nicolai N; Mariani L; Salvioni R
Ann Oncol; 2017 Jun; 28(6):1346-1351. PubMed ID: 28383677
[TBL] [Abstract][Full Text] [Related]
23. A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors.
Theodore C; Chevreau C; Yataqhene Y; Fizazi K; Delord JP; Lotz JP; Geoffrois L; Kerbrat P; Bui V; Flechon A
Ann Oncol; 2008 Aug; 19(8):1465-1469. PubMed ID: 18385203
[TBL] [Abstract][Full Text] [Related]
24. Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes.
Necchi A; Nicolai N; Mariani L; Lo Vullo S; Giannatempo P; Raggi D; Farè E; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Milani A; Gianni AM; Salvioni R
Clin Genitourin Cancer; 2014 Feb; 12(1):63-69.e1. PubMed ID: 24161525
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
Badreldin W; Krell J; Chowdhury S; Harland SJ; Mazhar D; Harding V; Frampton AE; Wilson P; Berney D; Stebbing J; Shamash J
BJU Int; 2016 Mar; 117(3):418-23. PubMed ID: 25430674
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
Bokemeyer C; Gerl A; Schöffski P; Harstrick A; Niederle N; Beyer J; Casper J; Schmoll HJ; Kanz L
J Clin Oncol; 1999 Feb; 17(2):512-6. PubMed ID: 10080593
[TBL] [Abstract][Full Text] [Related]
27. Phase II clinical trial of oxaliplatin and bevacizumab in refractory germ cell tumors.
Jain A; Brames MJ; Vaughn DJ; Einhorn LH
Am J Clin Oncol; 2014 Oct; 37(5):450-3. PubMed ID: 23388561
[TBL] [Abstract][Full Text] [Related]
28. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.
Powles T; Shamash J; Berney D; Oliver RT
Br J Cancer; 2003 Sep; 89(6):1140-1; author reply 1141-2. PubMed ID: 12966438
[No Abstract] [Full Text] [Related]
29. The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
Marwaha S; Venner PM; North SA
Can J Urol; 2007 Oct; 14(5):3692-6. PubMed ID: 17949524
[TBL] [Abstract][Full Text] [Related]
30. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
Zucali PA; De Pas T; Palmieri G; Favaretto A; Chella A; Tiseo M; Caruso M; Simonelli M; Perrino M; De Vincenzo F; Toffalorio F; Damiano V; Pasello G; Garbella E; Ali M; Conforti F; Ottaviano M; Cioffi A; De Placido S; Giordano L; Bertossi M; Destro A; Di Tommaso L; Santoro A
J Clin Oncol; 2018 Feb; 36(4):342-349. PubMed ID: 29240542
[TBL] [Abstract][Full Text] [Related]
31. [Results of the German studies (MAHO) for treatment of testicular germ cell tumors in children--an update].
Schmidt P; Haas RJ; Göbel U; Calaminus G
Klin Padiatr; 2002; 214(4):167-72. PubMed ID: 12165897
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors.
Oechsle K; Bokemeyer C; Honecker F
J Cancer Res Clin Oncol; 2010 Jan; 136(1):165-7. PubMed ID: 19760194
[TBL] [Abstract][Full Text] [Related]
33. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
Lorch A; Kollmannsberger C; Hartmann JT; Metzner B; Schmidt-Wolf IG; Berdel WE; Weissinger F; Schleicher J; Egerer G; Haas A; Schirren R; Beyer J; Bokemeyer C; Rick O;
J Clin Oncol; 2007 Jul; 25(19):2778-84. PubMed ID: 17602082
[TBL] [Abstract][Full Text] [Related]
34. Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.
Nakamura T; Ueda T; Oishi M; Nakanishi H; Fujihara A; Naya Y; Hongo F; Kamoi K; Okihara K; Miki T
Int J Urol; 2015 Mar; 22(3):288-93. PubMed ID: 25393104
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Massarelli E; Lin H; Ginsberg LE; Tran HT; Lee JJ; Canales JR; Williams MD; Blumenschein GR; Lu C; Heymach JV; Kies MS; Papadimitrakopoulou V
Ann Oncol; 2015 Jul; 26(7):1476-80. PubMed ID: 26025965
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial.
Mego M; Svetlovska D; Angelis V D; Kalavska K; Lesko P; Makovník M; Obertova J; Orszaghova Z; Palacka P; Rečková M; Rejlekova K; Z SM; Mardiak J; Chovanec M
Invest New Drugs; 2022 Oct; 40(5):1080-1086. PubMed ID: 35763178
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma.
Harstrick A; Schmoll HJ; Wilke H; Köhne-Wömpner CH; Stahl M; Schöber C; Casper J; Bruderek L; Schmoll E; Bokemeyer C
J Clin Oncol; 1991 Sep; 9(9):1549-55. PubMed ID: 1651992
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors in patients with relapsed or primary refractory germ cell tumors.
Rejlekova K; Mego M; Sycova-Mila Z; Obertova J; Rajec J; Salek T; Mardiak J
Neoplasma; 2009; 56(3):215-23. PubMed ID: 19309224
[TBL] [Abstract][Full Text] [Related]
39. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.
Johnston PB; Inwards DJ; Colgan JP; Laplant BR; Kabat BF; Habermann TM; Micallef IN; Porrata LF; Ansell SM; Reeder CB; Roy V; Witzig TE
Am J Hematol; 2010 May; 85(5):320-4. PubMed ID: 20229590
[TBL] [Abstract][Full Text] [Related]
40. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.
Escudier B; Molinie V; Bracarda S; Maroto P; Szczylik C; Nathan P; Negrier S; Weiss C; Porta C; Grünwald V; Albiges L
Eur J Cancer; 2016 Dec; 69():226-235. PubMed ID: 27680407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
